Granulox® Topical Haemoglobin Spray

Product Overview

Granulox® is a topical haemoglobin spray designed to oxygenate hard-to-heal wounds. It serves as an adjunct therapy to standard care, specifically targeting hypoxia (low oxygen levels), which is a primary driver of stalled healing in chronic wounds. By delivering oxygen directly to the wound bed through simplified diffusion, Granulox® helps restart the healing process in wounds that have failed to respond to standard treatment alone.

Mechanism of Action: Facilitated Diffusion

Granulox® functions as an oxygen transporter. When sprayed on a wound, the haemoglobin molecules perform a cyclical "shuttle" service:

1. Binding: The haemoglobin binds oxygen from the surrounding air.
2. Transport: It diffuses through the wound exudate to the wound bed.
3. Release: Driven by the oxygen gradient (moving from high concentration in the air to low concentration in the tissue), the haemoglobin releases the oxygen into the hypoxic cells.
4. Repeat: The process is reversible; after releasing the oxygen, the haemoglobin returns to the surface to bind more oxygen, maintaining a continuous supply.

Key Clinical Benefits

Clinical studies and real-world case reports highlight three primary areas of efficacy:

• Accelerated Wound Closure:
  • In a study of chronic venous leg ulcers, patients treated with Granulox® saw an average 53% reduction in wound size over 13 weeks, compared to a 21% increase in size for those on standard care alone.
  • In diabetic foot ulcers, 95% of wounds reduced in size with Granulox®, compared to 63% in the control group.
• Significant Pain Reduction:
  • Hypoxia induces nerve hypersensitivity. By correcting oxygen levels, Granulox® significantly lowers pain scores. One study showed an 86% mean reduction in pain scores after four weeks of treatment.
• Reduction of Sloughy Tissue:
  • Oxygenation helps clean the wound bed. Studies observed 99% less slough after four weeks of treatment compared to only 33% reduction with standard care.

Indications for Use

Granulox® is indicated for the management of chronic and hard-to-heal wounds, including:

• Diabetic foot ulcers.
• Venous, arterial, and mixed leg ulcers.
• Pressure ulcers.
• Post-surgical and traumatic wounds.
• Sloughy and infected wounds.

It is suitable for use alongside other advanced interventions, including negative pressure wound therapy (NPWT) and skin grafting.

Economic Value

By accelerating healing times, Granulox® can reduce the overall frequency of dressing changes and the total duration of treatment. A cost-effectiveness analysis indicated that adding Granulox® to standard care resulted in lower total treatment costs compared to standard care alone (£6,953 vs. £9,547) due to faster resolution of the wound.

Application & Usage

• Format: Portable spray.
• Frequency: Applied during dressing changes (e.g., twice weekly or daily depending on the regimen).
• Protocol: The wound should be cleaned and debrided prior to application. A thin film is sprayed onto the wound before the application of a breathable primary dressing.

Analogy for the Patient or Clinician: Imagine the wound exudate (fluid) as a wide river that oxygen needs to cross to get to the "construction site" (the damaged tissue) on the other bank. Oxygen is a poor swimmer and struggles to cross the river on its own. Granulox® acts as a ferry boat. It picks up oxygen passengers from the "air side," ferries them safely across the fluid river, drops them off at the construction site, and immediately heads back to pick up more. This ensures the workers (cells) always have the energy they need to rebuild.